PETALING JAYA - Malaysia's fight against dengue fever has been bolstered with the launch of a vaccine targeting the disease.
Takeda Malaysia today launched the Dengue Tetravalent Vaccine, Qdenga indicated for the prevention of dengue disease caused by all four dengue virus serotypes.
The vaccine was approved by The Drug Control Authority (DCA) Malaysia based on extensive data demonstrating its efficacy, safety, and quality.
It requires two doses at a three-month gap and can be administered to those aged four and above. Takeda Malaysia and Singapore Country General Manager Dr Lynette Moey said effective dengue prevention requires a multi-faceted approach.
"The availability of Qdenga is a crucial addition to the current integrated dengue prevention and management strategies in Malaysia.
"We are committed to partnering with local health authorities and health experts to ensure Qdenga is accessible to all eligible Malaysians who may benefit from immunisation.
"We deeply understand the importance of safeguarding our communities from dengue fever and recognize the transformative impact vaccines can have on public health," she said at the launch event held in One World Hotel.
According to Dr Moey, the vaccine provides sustained protection for up to 4.5 years, benefiting individuals with prior dengue exposure as well as those without any previous infection.
"In Malaysia, the vaccine is approved for individuals aged four and above. This wide range allows us to extend protection to a larger group of eligible Malaysians, including children, adults, and even senior citizens," she added.
Malaysians can now consult with their doctors and healthcare professionals in private hospitals and clinics to learn more about the vaccine for dengue prevention and protection.